Comparison of efficacy and safety between flunisolide/aerochamber and budesonide/turbuhaler in patients with moderate asthma

Annals of Allergy, Asthma and Immunology

Volumn 84, Issue 3, 2000, Pages 313-319

  Newhouse, Michael ^a   Knight, Allan ^c   Wang, Shanshan ^b   Newman, Kenneth ^b  

^a ST JOSEPH S HOSPITAL   (Canada)

^b FOREST RESEARCH INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; FLUNISOLIDE;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 0034062305     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62779-2     Document Type: Article

References (17)

1. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;332: 868-875.
2. Goldberg S, Algur N, Levi M, et al. Adrenal suppression among asthmatic children receiving chronic therapy with inhaled corticosteroid with and without spacer device. Ann Allergy Asthma Immunol 1996;76:234-238.
3. Hanania NA, Chapman KR, Sturtridge WC, et al. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995;96: 571-579.
4. Kiviranta K, Turpeinen M. Effect of eight months of inhaled beclomethasone dipropionate and budesonide on carbohydrate metabolism in adults with asthma. Thorax 1993;48: 974-978.
5. Nicolaizik WH, Marchant JL, Preece MA, Warner JO. Endocrine and lung function in asthmatic children on inhaled corticosteroids. Am J Respir Crit Care Med 1994;150:624-628.
6. Pavia D. Efficacy and safety of inhalation therapy in chronic obstructive pulmonary disease and asthma. Respirology 1997;2(Suppl 1):S5-S10.
7. Conner WT, Dolovich MB, Frame RA, Newhouse MT. Reliable salbutamol administration in 6-to 36-month-old children by means of a metered dose inhaler and Aerochamber with mask. Pediatr Pulmonol 1989;6:263-267.
8. Dolovich M, Ruffin R, Corr D, Newhouse MT. Clinical evaluation of a simple demand inhalation MDI aerosol delivery device. Chest 1983;84:36-41.
9. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994;7:1839-1844.
10. Salzman GA, Pyszczynski DR. Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with Aerochamber. J Allergy Clin Immunol 1988;81:424-428.
11. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998;132:976-982.
12. Chua HL, Chambers CB, Newhouse MT. Upper respiratory tract salbutamol deposition following MDI and AeroChamber: effect of mouth rinsing on oropharyngeal clearance. J Aerosol Med 1995;8:83.
13. Ahrens R, Lux C, Bahl T, Han SH. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: evidence that the specific drug being delivered is an important consideration. J Allergy Clin Immunol 1995;96:288-294.
14. National Asthma Education and Prevention Program. Clinical Practice Guidelines. Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health; April 1997. Publication 97-4051.
15. American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am Rev Respir Dis 1991;144:1202-1218.
16. Ebden P, Jenkins A, Houston G, Davies BH. Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (155 micrograms/day) and budesonide (1600 micrograms/day), for chronic asthma. Thorax 1986;41: 869-874.
17. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother 1998; 32:220-232.